Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy

  • Technology appraisal guidance
  • TA1115
  • Published: 

Suggested remit: To appraise the clinical and cost effectiveness of Vutrisiran within its marketing authorisation for treating amyloidosis.

This page was last updated: